DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: NORVIR

Summary for Tradename: NORVIR

Patents:17
Applicants:2
NDAs:4
Suppliers: see list1
drug
patent expirations by year for
 NORVIR

Clinical Trials for: NORVIR

Bioequivalence Study of Generic GPO Ritonavir Versus Norvir®
Status: Completed Condition: Healthy

Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®
Status: Withdrawn Condition: HIV Infections

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects
Status: Completed Condition: HIV Infections

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
Status: Completed Condition: Human Immunodeficiency Virus Type 1 (HIV-1); HIV Infections

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
Status: Completed Condition: HIV Infections; Hyperlipidemia

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
Status: Active, not recruiting Condition: HIV Infections

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
Status: Active, not recruiting Condition: HIV Infections

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
Status: Completed Condition: Healthy Volunteer

Drug Interaction Study With Darunavir/Ritonavir or Lopinavir/Ritonavir and Daclatasvir
Status: Completed Condition: Hepatitis C

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945Jun 29, 1999RXYes5,541,206*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945Jun 29, 1999RXYes5,635,523*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945Jun 29, 1999RXYes5,648,497*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945Jun 29, 1999RXYes5,674,882*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NORVIR

Drugname Dosage Strength RLD Submissiondate
ritonavirCapsules100 mgNorvir10/31/2012
ritonavirTablets100 mgNorvir12/21/2010

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc